Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
Identifieur interne : 000558 ( PubMed/Checkpoint ); précédent : 000557; suivant : 000559Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
Auteurs : Azar Hadadi [Iran] ; Masoud Mortezazadeh [Iran] ; Kasra Kolahdouzan [Iran] ; Golbarg Alavian [Iran]Source :
- Journal of medical virology [ 1096-9071 ] ; 2020.
Abstract
An 80-year-old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever and critically low O2 saturation and definitive chest CT scan findings in favor of COVID-19 and positive PCR results in 48 h. He received antiviral treatment plus recombinant human Erythropoietin(rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the SARS-CoV-2 virus through multiple mechanisms including cytokine modulation, anti-apoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus. This article is protected by copyright. All rights reserved.
DOI: 10.1002/jmv.25839
PubMed: 32270515
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32270515Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?</title><author><name sortKey="Hadadi, Azar" sort="Hadadi, Azar" uniqKey="Hadadi A" first="Azar" last="Hadadi">Azar Hadadi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Mortezazadeh, Masoud" sort="Mortezazadeh, Masoud" uniqKey="Mortezazadeh M" first="Masoud" last="Mortezazadeh">Masoud Mortezazadeh</name><affiliation wicri:level="1"><nlm:affiliation>Internal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Internal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Kolahdouzan, Kasra" sort="Kolahdouzan, Kasra" uniqKey="Kolahdouzan K" first="Kasra" last="Kolahdouzan">Kasra Kolahdouzan</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Institute, Radiation Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Cancer Institute, Radiation Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Alavian, Golbarg" sort="Alavian, Golbarg" uniqKey="Alavian G" first="Golbarg" last="Alavian">Golbarg Alavian</name><affiliation wicri:level="1"><nlm:affiliation>Pharmacotherapy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Pharmacotherapy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32270515</idno><idno type="pmid">32270515</idno><idno type="doi">10.1002/jmv.25839</idno><idno type="wicri:Area/PubMed/Corpus">000267</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000267</idno><idno type="wicri:Area/PubMed/Curation">000267</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000267</idno><idno type="wicri:Area/PubMed/Checkpoint">000558</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000558</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?</title><author><name sortKey="Hadadi, Azar" sort="Hadadi, Azar" uniqKey="Hadadi A" first="Azar" last="Hadadi">Azar Hadadi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Mortezazadeh, Masoud" sort="Mortezazadeh, Masoud" uniqKey="Mortezazadeh M" first="Masoud" last="Mortezazadeh">Masoud Mortezazadeh</name><affiliation wicri:level="1"><nlm:affiliation>Internal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Internal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Kolahdouzan, Kasra" sort="Kolahdouzan, Kasra" uniqKey="Kolahdouzan K" first="Kasra" last="Kolahdouzan">Kasra Kolahdouzan</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Institute, Radiation Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Cancer Institute, Radiation Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Alavian, Golbarg" sort="Alavian, Golbarg" uniqKey="Alavian G" first="Golbarg" last="Alavian">Golbarg Alavian</name><affiliation wicri:level="1"><nlm:affiliation>Pharmacotherapy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Pharmacotherapy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An 80-year-old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever and critically low O2 saturation and definitive chest CT scan findings in favor of COVID-19 and positive PCR results in 48 h. He received antiviral treatment plus recombinant human Erythropoietin(rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the SARS-CoV-2 virus through multiple mechanisms including cytokine modulation, anti-apoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus. This article is protected by copyright. All rights reserved.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32270515</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25839</ELocationID><Abstract><AbstractText>An 80-year-old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever and critically low O2 saturation and definitive chest CT scan findings in favor of COVID-19 and positive PCR results in 48 h. He received antiviral treatment plus recombinant human Erythropoietin(rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the SARS-CoV-2 virus through multiple mechanisms including cytokine modulation, anti-apoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus. This article is protected by copyright. All rights reserved.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hadadi</LastName><ForeName>Azar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortezazadeh</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-3585-9379</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolahdouzan</LastName><ForeName>Kasra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cancer Institute, Radiation Oncology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alavian</LastName><ForeName>Golbarg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pharmacotherapy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute Respiratory Distress Syndrome</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokine</Keyword><Keyword MajorTopicYN="N">Erythropoietin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32270515</ArticleId><ArticleId IdType="doi">10.1002/jmv.25839</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Iran</li></country></list><tree><country name="Iran"><noRegion><name sortKey="Hadadi, Azar" sort="Hadadi, Azar" uniqKey="Hadadi A" first="Azar" last="Hadadi">Azar Hadadi</name></noRegion><name sortKey="Alavian, Golbarg" sort="Alavian, Golbarg" uniqKey="Alavian G" first="Golbarg" last="Alavian">Golbarg Alavian</name><name sortKey="Kolahdouzan, Kasra" sort="Kolahdouzan, Kasra" uniqKey="Kolahdouzan K" first="Kasra" last="Kolahdouzan">Kasra Kolahdouzan</name><name sortKey="Mortezazadeh, Masoud" sort="Mortezazadeh, Masoud" uniqKey="Mortezazadeh M" first="Masoud" last="Mortezazadeh">Masoud Mortezazadeh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000558 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000558 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32270515
|texte= Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32270515" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |